Rigin (Palmitoyl Tetrapeptide-7)

Rigin is a palmitoylated tetrapeptide fragment of immunoglobulin G that modulates interleukin-6 production and matrix metalloproteinase activity. It is studied for its immunostimulatory, neurotrophic, and skin-rejuvenating properties.

Rigin (Palmitoyl Tetrapeptide-7) is a palmitoylated fragment of the IgG antibody (amino acids 341-344 of the human IgG heavy chain) that stimulates collagen production and inhibits inflammatory cytokines. It is of primary scientific interest for its ability to improve skin elasticity, firmness, and hydration through modulation of interleukin-6 and matrix metalloproteinase activity.

Overview

Rigin is a compound in which a fragment of immunoglobulin G (IgG) has been attached to a fatty acid residue (palmitoyl). The term "rigin" can refer either to the IgG fragment alone or to the full palmitoyl-Gly-Gln-Pro-Arg molecule. Originally developed as a potential immunostimulatory and neurotrophic peptide, rigin is still under active investigation for its ability to encourage nerve healing, particularly after burns and tissue grafts. More recently, interest has increased among researchers studying extracellular matrix (ECM) modulation, as rigin influences collagen and elastin synthesis and can improve skin elasticity and firmness in animal models.

Mechanism of Action

Rigin modulates the production of interleukin-6 (IL-6), a signaling molecule produced by T-cells that recruits immune cells to sites of injury or infection. When the immune response becomes excessive, it can damage healthy tissue, leading to breakdown of collagen and elastin in the extracellular matrix. By counteracting excessive IL-6 signaling, rigin reduces collateral immune-mediated skin damage.

Rigin also downregulates matrix metalloproteinases (MMPs), a group of enzymes involved in the breakdown of ECM proteins during normal tissue turnover. By reducing MMP activity, rigin allows cells that restore and maintain the ECM to better keep pace with the effects of aging. This dual action on IL-6 and MMPs is functionally similar, in some respects, to dehydroepiandrosterone (DHEA).

Reconstitution Calculator

Reconstitution Calculator

Calculate your peptide dosing

Draw Volume
0.100mL
Syringe Units
10units
Concentration
2,500mcg/mL
Doses / Vial
20doses
Vial Total
5mg
Waste / Vial
0mcg
Syringe Cap.
100units · 1mL
How to reconstitute
Gather & prepare
1/6Gather & prepare

Set up a clean workspace with all supplies ready.

1.Wash hands thoroughly, put on disposable gloves
2.Your 5mg peptide vial (lyophilized powder)
3.Bacteriostatic water (you'll need 2mL)
4.A 3–5mL syringe with 21–25 gauge needle for reconstitution
5.Alcohol swabs (70% isopropyl)
Use bacteriostatic water (0.9% benzyl alcohol) for multi-dose vials. Sterile water is only safe for single-use.
Supply Planner

7x / week for weeks

·
40%
2vials
28 doses20 days/vial12 leftover
Cost Breakdown
Vial price
$0.00per dose
$0.00 /week$0 /month
Store 2-8°C30 day shelf lifeSwirl gentlyFor research purposes only

Research

Immunostimulatory and Neurotrophic Effects

Rigin was developed after the related tetrapeptide tuftsin was found to have immunostimulatory and neurotrophic activities. Hydrophobic analogues of rigin have demonstrated immunomodulatory potential and protective effects against Plasmodium berghei infection in mouse models. Dutta et al. (2001) — Int. Immunopharmacol.

Anti-Inflammatory Skin Protection

Based on observations from animal research and human skin cell studies, rigin reduces the appearance of fine lines and wrinkles while evening out skin tone, improving elasticity, and increasing hydration. Rigin is often combined with other ingredients such as palmitoyl oligopeptide (as in Matrixyl 3000) to create synergistic effects that enhance skin rejuvenation.

Skin Rejuvenation and ECM Modulation

Research using matrix-assisted laser desorption/ionization mass spectrometric imaging, confocal microscopy, and histological analysis has demonstrated that peptide applications including rigin can modify dermal extracellular matrix and epidermal-dermal junction structure. These modifications are associated with improved skin elasticity and reduced signs of aging. Mondon et al. (2015) — J. Cosmet. Dermatol.

MMP Modulation

Matrix metalloproteinases play a central role in ECM degradation in both oral and skin tissues. By downregulating MMP activity, rigin can reduce ECM damage associated with aging and chronic inflammation. Sorsa et al. (2004) — Oral Dis.

Safety Profile

Rigin (Palmitoyl Tetrapeptide-7) is generally well-tolerated in topical formulations. As a cosmetic peptide ingredient, it has been used in commercially available skincare products with no significant adverse effects reported. No systemic toxicity data are available, as rigin is primarily administered topically. Individuals with known hypersensitivity to peptide-based cosmetic ingredients should exercise caution. No significant drug interactions have been identified in topical applications.

Pharmacokinetic Profile

Half-life
Not established

Quick Start

Route
Topical

Molecular Structure

Molecular Properties
Formula
C34H62N8O7
Weight
694.9 Da
CAS
221227-05-0

Research Protocols

oral

MMP Modulation Matrix metalloproteinases play a central role in ECM degradation in both oral and skin tissues.

topical

No systemic toxicity data are available, as rigin is primarily administered topically. No significant drug interactions have been identified in topical applications.

Interactions

Peptide Interactions

Matrixylsynergistic

Rigin is often combined with other ingredients such as palmitoyl oligopeptide (as in Matrixyl 3000) to create synergistic effects that enhance skin rejuvenation.

Quality Indicators

What to look for

  • Well-established safety profile

Frequently Asked Questions

References (5)

  1. [4]
  2. [6]
  3. [2]
  4. [3]
    Sorsa, T., Tjaderhane, L. & Salo, T Matrix metalloproteinases (MMPs) in oral diseases Oral Dis. (2004)
  5. [1]
    Dutta, R. C., Puri, A. & Anand, N Immunomodulatory potential of hydrophobic analogs of Rigin Int. Immunopharmacol. (2001)
Updated 2026-03-08Reviewed by Tides Research Team3 citationsSources: peptide-wiki-mdx, peptide-wiki-mdx-v2

On this page